| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b105419ca434d643a47607a98b8c9c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-495 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-495 |
| filingDate |
2011-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4e0ea761e7e6628e833816b264a31e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70241e323a07b4d84015e634c86b03b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d98a3201ee90bfe0553a53103b924889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1150c5cf2f741f4232db5995e594484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6c6f03115138d069f7b72971265af15 |
| publicationDate |
2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103003424-B |
| titleOfInvention |
Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation |
| abstract |
Among antibodies exhibiting reactivity to natural TGF[alpha], antibodies having low reactivity to G79A-substituted TGF[alpha] are identified as exhibiting superior antiproliferative activity against cancer cells having a mutation in the Ras gene. Further identified is that many of the antibodies also inhibit the tyrosine phosphorylation of EGFR and/or inhibit the induction of vascular endothelial cells. |
| priorityDate |
2010-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |